Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1NSCLC 1Mucopolysaccharidosis I 1Metastatic Castration-resistant Prostate Cancer 1Liposarcoma 1Hodgkin Disease 1Disease Progression 1Carcinoma in Situ 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × Clinical Trials, Phase I as Topic × Clear all
NCT04503265 2025-05-01

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AtlasMedx, Incorporated

Phase 1/2 Recruiting
122 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Disease Progression

NCT03411161 2021-05-25

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Servier

Phase 1/2 Completed
22 enrolled
Breast

Breast Neoplasms, Mucopolysaccharidosis I, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡